■ A recent consensus panel of 10 international glaucoma experts discussed Iridex’s Micropulse transscleral laser therapy (TLT) and their recommendations for dosing, optimization, and patient selection. After thoroughly analyzing the clinical, technical, and practical experience to date, the group has created a consensus document with guidance for the clinical application of Micropulse TLT around the world.
The panel answered 16 questions during the discussion, covering relevant aspects of using the laser in actual treatment scenarios. These questions addressed treatment optimization and settings with the revised Micropulse P3 Probe, along with the importance of sweep speed, and identified prime clinical drivers for patient selection, outcomes, and safety.
The consensus of this panel is that the standard MicroPulse TLT settings using the revised Micropulse P3 Probe should be 2,500 MW, 31.3% duty cycle, and 4 sweeps of 20 seconds each per hemisphere (4 sweeps of 10 seconds each per quadrant).
In a statement from Iridex, the consensus group ultimately agreed that “Micropulse TLT can be safely performed in patients with POAG and ACG. Various types of secondary glaucoma can be treated with Micropulse TLT.”